Research Topics
| R HastSummaryAffiliation: Karolinska Institutet Country: Sweden Publications
|
Detail Information
Publications
Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatmentR Hast
Division of Hematology, Department of Medicine, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden
Leuk Res 25:13-18. 2001..Long-term responses were seen in about a third of the patients. Thus, it seems safe to reduce the EPO dose among responding patients. This approach may have advantages both from a medical and a socio-economic perspective...- Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemiaR Hast
Department of Medicine, Danderyd Hospital, Stockholm, Sweden
Leuk Lymphoma 34:597-601. 1999..No severe infectious complications were noted. The use of purine analogues should be investigated further in AILD... - Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trialC Lofgren
Huddinge University Hospital, Stockholm, Sweden
Br J Haematol 124:474-80. 2004..GM-CSF prior to, and in combination with, induction treatment reduced the time to neutrophil recovery and the number of neutropenic septicaemia cases but did not improve the OS of AML in the elderly... - Trisomy 12 and lymphoplasmacytoid lymphocytes in chronic leukemic B-cell disordersV Hjalmar
Department of Medicine, Karolinska Institutet, Danderyd Hospital, Sweden
Haematologica 83:602-9. 1998.... - DNA image cytometry in MDS bone marrow smearsS Widell
Division of Cell and Molecular Analysis, Karolinska Hospital, Stockholm, Sweden
Br J Haematol 105:960-5. 1999..No difference between groups of MDS patients was found. DNA hypodiploidy is suggested to be a common feature in MDS without a relationship to cytogenetics... - Atypical lymphocytes in B-cell chronic lymphocytic leukemia and trisomy 12 studied by conventional staining combined with fluorescence in situ hybridizationV Hjalmar
Division of Hematology, Department of Medicine, Karolinska Hospital, Karolinska Institutet, Stockholm, Sweden
Leuk Lymphoma 37:571-6. 2000..This supports that both cell types have the same clonal origin and that different cell morphology cannot be explained alone by the acquisition of an additional chromosome 12... - Sequential fluorescence in situ hybridization analyses for trisomy 12 in chronic leukemic B-cell disordersV Hjalmar
Division of Hematology, Karolinska Hospital, SE 171 76 Stockholm, Sweden
Haematologica 86:174-80. 2001..The aberration is readily detected by fluorescence in situ hybridization (FISH). There are only a few reports in which FISH analyses have been used to study the expansion of the trisomy 12 clone over time... - Imipenem/cilastatin monotherapy as salvage treatment in febrile neutropenic patientsP Engervall
Department of Medicine, Karolinska Hospital, Stockholm, Sweden
J Chemother 8:382-6. 1996..In conclusion, the use of a treatment algorithm with I/C monotherapy as second-line treatment was safe and effective. Other antimicrobial agents, most often vancomycin and/or amphotericin B, had to be added in half of the patients... - Masked monosomy 7 in myelodysplastic syndromes is uncommon and of undetermined clinical significanceK Jakovleva
Department of Hematology, Division of Medicine, Karolinska Hospital, Karolinska Institutet, SE-171 76 Stockholm, Sweden
Leuk Res 25:197-203. 2001..Thus, masked monosomy 7 is less common than has been suggested, and does not seem to carry the same prognostic weight as monosomy 7 diagnosed by metaphase cytogenetics... - No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative diseaseR Hast
Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
Leukemia 17:1827-33. 2003..We present a clinically useful tool to predict response to chemotherapy and survival in elderly patients with transforming MDS, favoring patients with features of less proliferative disease... - Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central SwedenA Osterborg
Department of Oncology, Karolinska Hopital, Stockholm, Sweden
Acta Oncol 29:727-31. 1990..Since intravenous administration of melphalan did not result in a substantial increase in response rate or survival, this study supports the use of oral melphalan/prednisone as first-line therapy for patients with multiple myeloma... - DNA content of granulocytes, monocytes, and lymphocytes in the bone marrow smears of patients with myelodysplastic syndromesS Widell
Cancer Center, Department of Oncology and Pathology, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden
Am J Hematol 67:112-8. 2001..Clonality, by means of DNA content, appears reasonable as regards the granulocytes and monocytes. DNA hypodiploid lymphocytes, on the other hand, might be small blasts (stem cells) or dying cell populations of unknown origin...